RecruitingACTRN12623000904673

Paediatric Asthma and Wheeze Study - Part 1

Using a wheeze scan device (WheezeScan) for the management of preschool wheeze and paediatric asthma: a multicentre cohort study - Part 1


Sponsor

Queensland University of Technology

Enrollment

102 participants

Start Date

Feb 1, 2024

Study Type

Interventional

Conditions

Summary

Wheeze, a breath sound that may indicate asthma, is very common in children; ~50% of all preschool aged children have an episode of wheeze and 40% of these children have recurrent wheeze. Also, asthma is the most common chronic illness in children. Yet, identifying wheeze is challenging for parents (disagreement rate between doctors and parents are >50%) and indeed many cultures (including Indigenous Aus) do not have a word for wheeze. Our multicentre study addresses the need to define wheeze accurately using digital technology. We will use WheezeScan (WzS) digital technology during face-to-face clinics as well as remotely (child’s home) in Queensland (including outreach clinics), Darwin and Sydney. Recruiting children from the hospitals and outreach clinics, we plan a cohort study involving 102 preschool children suspected of having asthma. We aim to determine whether using WzS improves the diagnosis of asthma, patient related outcomes (PROs) and health cost. WzS’s dependable accuracy will provide parents/caregivers and doctors the ability to discern if a child is wheezing-subsequently providing the confidence and clarity over the next steps that need actioning. Our study will improve the detection and consequently the management of preschool wheeze by the accurate diagnosis of reversible airway obstruction/asthma. Our proposal will fulfil a large unmet clinical need and research gap, identified by our patients, parents, parent advisory group, clinicians, Asthma Foundation of NT, as well as Australian data and international surveys.


Eligibility

Sex: Both males and femalesMin Age: 6 MonthssMax Age: 6 Yearss

Plain Language Summary

Simplified for easier understanding

Wheeze — the whistling breathing sound often associated with asthma — is very common in young children, but parents and doctors disagree about whether wheeze is present more than half the time. This makes it hard to diagnose asthma accurately in preschool-aged children, who cannot yet reliably perform formal breathing tests. This study is testing WheezeScan (WzS), a digital tool that can detect wheeze during clinic visits or remotely from home. The study will recruit 102 children aged 6 months to 6 years who have been seen for suspected asthma (such as two or more episodes of wheeze, a persistent cough, or breathlessness with activity). Researchers will use WheezeScan to find out whether it improves how accurately asthma is diagnosed in this age group, and whether it improves outcomes for patients and families while also reducing healthcare costs. Your child may be eligible if they are aged 6 months to 6 years and have been reviewed for suspected asthma at a participating clinic in Queensland, Darwin, or Sydney. Children with a known specialist diagnosis of asthma, chronic wet cough suggesting a different lung condition, or who have already been enrolled are not eligible. The study is led by Queensland University of Technology.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Use of WheezeScan (WzS), a portable user-friendly digital device that listens to 30sec of breathing then objectively documents wheeze using AI-informed signal processing. WzS is manufactured by Omron

Use of WheezeScan (WzS), a portable user-friendly digital device that listens to 30sec of breathing then objectively documents wheeze using AI-informed signal processing. WzS is manufactured by Omron (Japan). Parents will be trained by the research nurses/assistants using a standard protocol provided by the manufacturers (sse link https://www.omron-healthcare.co.uk/nebulisers/wheezescan.html). Adherence will be monitored using participant diaries. Wheezescan will be used at least once a day over the study period of 5 weeks.


Locations(4)

Queensland Children's Hospital - South Brisbane

NSW,NT,QLD, Australia

Gold Coast University Hospital - Southport

NSW,NT,QLD, Australia

The Children's Hospital at Westmead - Westmead

NSW,NT,QLD, Australia

Royal Darwin Hospital - Tiwi

NSW,NT,QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12623000904673


Related Trials